Carlyle and Leading Healthcare-Focused Venture Funds Announce Strategic Growth Investment of up to $430 Million in Saama
Retrieved on:
星期三, 十月 20, 2021
Data Management, Other Health, Technology, Pharmaceutical, General Health, Professional Services, Venture Capital, Clinical Trials, Other Technology, Biotechnology, Science, Software, Other Science, Internet, Research, Health, Cloud, Clinical trial, CG, NASDAQ, Guggenheim, Martha Plimpton, Digital, LSAC, View, Data management, COVID-19, EFront Alternative Investment Solutions, GHI, Drug development, Health, Oliver Cromwell, Digital health, Research, Vaccine, CEO, Solution, Patient, NDAS, Industry, Â, HarbourVest Global Private Equity, Partnership, Investment, Sullivan & Cromwell, Company, Pharmaceutical industry, Saama Technologies, Inc., Carlyle, Merck Global Health Innovation Fund, SAAMA TECHNOLOGIES, INC., CARLYLE, MERCK GLOBAL HEALTH INNOVATION FUND
Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.
Key Points:
- Saama Technologies, Inc. (Saama) today announced funds led by global investment firm Carlyle (NASDAQ: CG) have made a strategic growth investment and will acquire a majority stake in the Company.
- The partnership will allow Saama to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.
- Saamas intelligent Life Science Analytics Cloud (LSAC) is used by over 50 pharma and biotech companies on more than 1,500 studies.
- This investment by Carlyle and leading healthcare-focused venture funds reflects the value they see in Saamas leadership of this new era and the promise offered by our state-of-the-art solutions.